ARCHIVES

FDA Approval of Abraxane Sets Stage for Competition Between Taxane Drugs. Abraxane a Nanotechnology Drug? Sponsor Says Yes, FDA Says.

This article is from The Cancer Letter archive.

Vol. 31 No. 02 | January 14, 2005

Download PDF Visit The Full Archive

Related Articles

New Grant Program To Fund Partnerships Between Academia, Industry, Non-Profits

March 14, 2003

In Brief: Sullivan Rejects Oregon Medicaid Rationing Plan; Howe To Head National Marrow Donor Program

August 7, 1992

Adriamycin Update Discussed At Seminar

January 10, 1975

In Brief: GM Prizes: Einhorn, McMahon, Nusslein-Volhard; James, Poznanski Lead Roentgen Ray Society

June 26, 1992

In Brief: Reynolds Retires “Joe Camel” advertising; Slaga Moves Lab To MC Cancer Center

July 18, 1997

In Brief: Accidents Claim Wisconsin’s William Caldwell, John Wear; Murchison, Nance To Head Nalsi

June 15, 1979